TPST · Tempest Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $114.0K | - | $570.0K | $3.87M | $7.63M | - | $7.56M | $5.84M | $4.34M | - |
| SG&A | $5.42M | - | $3.03M | $4.09M | $3.31M | - | $2.99M | $3.75M | $3.63M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $60.0K | - | $66.0K | $67.0K | $68.0K | - | $98.0K | $155.0K | $88.0K | - |
| Operating Income | ($27.72M) | - | ($3.60M) | ($7.97M) | ($10.94M) | - | ($10.55M) | ($9.58M) | ($7.97M) | - |
| Interest Expense | $0 | - | $0 | $46.0K | $368.0K | - | $329.0K | $372.0K | $368.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($27.70M) | - | ($3.51M) | ($7.87M) | ($10.86M) | - | ($10.56M) | ($9.57M) | ($7.90M) | - |
| EPS - Basic | ($2.53) | - | ($0.79) | ($2.07) | ($3.16) | - | ($5.33) | ($5.46) | ($4.68) | - |
| EPS - Diluted | ($2.53) | - | ($0.79) | ($2.07) | ($3.16) | - | ($5.33) | ($5.46) | ($4.68) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.80M | $7.71M | $7.51M | $14.28M | $21.51M | $30.27M | $22.12M | $31.12M | $32.33M | $39.23M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $585.0K | $1.04M | $922.0K | $4.72M | $2.19M | $2.45M | $1.70M | $1.36M | $1.05M | $845.0K |
| Current Assets | $2.45M | $8.27M | $8.10M | $15.10M | $22.43M | $31.47M | $23.55M | $31.55M | $33.50M | $40.36M |
| Total Assets | $10.75M | $16.93M | $17.13M | $24.48M | $32.16M | $41.49M | $33.84M | $42.17M | $44.38M | $51.60M |
| Current Liabilities | $3.31M | $3.31M | $3.52M | $7.14M | $13.18M | $14.22M | $13.97M | $14.56M | $10.69M | $9.41M |
| Long-term Debt | - | - | - | - | $4.20M | $0 | $0 | $2.01M | $4.14M | $6.26M |
| Total Liabilities | $9.93M | $10.26M | $10.78M | $14.70M | $21.03M | $22.36M | $22.38M | $25.23M | $23.75M | $24.84M |
| Stockholders' Equity | $822.0K | $6.67M | $6.35M | $9.78M | $11.13M | $19.13M | $11.46M | $16.94M | $20.63M | $26.77M |
| Retained Earnings | ($270.07M) | ($233.37M) | ($229.35M) | ($225.84M) | ($217.97M) | ($207.11M) | ($193.29M) | ($182.74M) | ($173.17M) | ($165.26M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.60M) | - | - | - | ($8.04M) | - | - | - | ($7.19M) | - |
| Investing Cash Flow | $0 | - | - | - | $0 | - | - | - | ($168.0K) | - |
| Financing Cash Flow | $1.70M | - | - | - | ($721.0K) | - | - | - | $450.0K | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | $168.0K | - |
| Free Cash Flow | ($7.60M) | - | - | - | ($8.04M) | - | - | - | ($7.35M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.27 | - | - | - | 0.74 | - | - | - | 0.93 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -257.7% | - | -20.5% | -32.1% | -33.8% | - | -31.2% | -22.7% | -17.8% | - |
| Return on equity | -3369.3% | - | -55.3% | -80.4% | -97.5% | - | -92.1% | -56.5% | -38.3% | - |
| Return on invested capital | - | - | - | - | -56.3% | - | -72.8% | -40.0% | -25.4% | - |
| Liquidity | ||||||||||
| Current ratio | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 | 2.17 | 3.13 | 4.29 |
| Quick ratio | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 | 2.17 | 3.13 | 4.29 |
| Cash ratio | 0.55 | 2.33 | 2.13 | 2.00 | 1.63 | 2.13 | 1.58 | 2.14 | 3.02 | 4.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | 0.38 | 0.00 | 0.00 | 0.12 | 0.20 | 0.23 |
| Debt / Assets | - | - | - | - | 0.13 | 0.00 | 0.00 | 0.05 | 0.09 | 0.12 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | -173.2x | -29.7x | - | -32.1x | -25.8x | -21.7x | - |
| Equity multiplier | 13.08 | 2.54 | 2.70 | 2.50 | 2.89 | 2.17 | 2.95 | 2.49 | 2.15 | 1.93 |
| Liabilities / Assets | 0.92 | 0.61 | 0.63 | 0.60 | 0.65 | 0.54 | 0.66 | 0.60 | 0.54 | 0.48 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 21.8x | - | 7.2x | 2.6x | 3.0x | - | 41.0x | 37.9x | 54.8x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -153.5% | - | 65.9% | 16.9% | -37.1% | - | -60.1% | -28.3% | -5.2% | - |
| Net income growth (YoY) | -155.0% | - | 66.7% | 17.8% | -37.4% | - | -55.6% | -26.2% | -3.5% | - |
| EPS growth (YoY) | 19.9% | - | 85.2% | 62.1% | 32.5% | - | -1010.4% | -911.1% | -750.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 5.5% | - | - | - | -9.3% | - | - | - | 11.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -92.6% | -65.1% | -44.6% | -42.2% | -46.0% | -28.5% | - | 238.0% | 88.2% | 47.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tempest Therapeutics against the 5 most active filers in the same SIC group.